Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vilanterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 0.82 |
| ▸ | ADRB1 | P08588 | 15/20 | 0.82 |
| ▸ | ADRB3 | P13945 | 15/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.81 |
| ▸ | HTR2A | P28223 | 2/20 | 0.81 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.81 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.81 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.81 |
| ▸ | MLNR | O43193 | 1/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.81 |
| ▸ | DRD1 | P21728 | 1/20 | 0.81 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.81 |
| ▸ | MC3R | P41968 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.81 |
| ▸ | GHSR | Q92847 | 1/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vilanterol SCHEMBL164639 | 1.00 | ADRB2 (0.82) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL25268141 | 1.00 | ADRB2 (0.82) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL29150309 | 0.91 | ADRB2 (0.86) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| SCHEMBL23734612 | 0.91 | ADRB2 (0.68) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Acetic Acid SCHEMBL925230 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL29448201 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL925229 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL15614685 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| Vilanterol SCHEMBL142630 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A | |
| SCHEMBL17031687 | 0.90 | ADRB2 (1.00) | ADRB2ADRB1ADRB3SLC6A2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732870-A2 | BLISTER PACK AND INHALER COMPRISING THE SAME | Norton (Waterford) Limited (IE) | 2026-04-29 | — | — | EP | claimed |
| EP-4487892-B1 | BLISTER PACK AND INHALER COMPRISING THE SAME | NORTON WATERFORD LTD (IE) | 2026-04-15 | — | — | EP | claimed |
| EP-4706711-A2 | DRY POWDER MEDICAMENT INHALER | Norton (Waterford) Limited (IE) | 2026-03-11 | — | — | EP | claimed |
| EP-4452924-B1 | PROCESS TO PREPARE VILANTEROL TRIFENATATE | HOVIONE SCIENTIA LTD (IE) | 2025-12-03 | — | — | EP | claimed |
| EP-4331647-B1 | DRY POWDER MEDICAMENT INHALER | NORTON WATERFORD LTD (IE) | 2025-12-03 | — | — | EP | claimed |
| EP-4642463-A1 | PHARMACEUTICAL COMPOSITIONS OF GREEN PROPELLANT | Cipla Limited (IN) | 2025-11-05 | — | — | EP | claimed |
| EP-3880169-B1 | UMECLIDINIUM AND VILANTEROL FORMULATION AND INHALER | KINDEVA DRUG DELIVERY LP (US) | 2025-07-23 | — | — | EP | claimed |
| EP-4582081-A1 | PHARMACEUTICAL FORMULATION COMPRISING COMBINATION OF LONG-ACTING INHALED STEROID AND LONG-ACTING BETA2 RECEPTOR AGONIST | Lexenpharm (Suzhou) Limited (CN) | 2025-07-09 | — | — | EP | claimed |
| US-20250195544-A1 | FLUTICASONE FUROATE IN THE TREATMENT OF COPD | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-06-19 | — | — | US | claimed |
| EP-4548953-A2 | DRY POWDER MEDICAMENT INHALER | Norton (Waterford) Limited (IE) | 2025-05-07 | — | — | EP | claimed |
| US-11434194-B2 | Amorphous form of vilanterol trifenatate and processes for the preparation thereof | HOVIONE SCIENTIA LIMITED (IE) | 2022-09-06 | — | — | US | claimed |
| US-11414374-B2 | Crystalline forms of vilanterol trifenatate and processes for their preparation | HOVIONE SCIENTIA LIMITED (IE) | 2022-08-16 | — | — | US | claimed |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ANOVENT PHARMACEUTICAL (U.S.), LLC (US) | 2022-06-28 | — | — | US | claimed |
| EP-4013398-A1 | AN IMPROVED PROCESS FOR PREPARATION OF VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Melody Healthcare Pvt. Ltd. (IN) | 2022-06-22 | — | — | EP | claimed |
| WO-2022118220-A1 | COMPOSITIONS, DEVICES, AND METHODS FOR TREATING RESPIRATORY DISORDERS | BREATHE RESTORE, INC. (US) | 2022-06-09 | — | — | WO | claimed |
| US-20220168516-A1 | PRODUCT DELIVERY DEVICES AND METHODS | BREATHE RESTORE, INC. | 2022-06-02 | — | — | US | claimed |
| EP-3996672-A1 | AEROSOL FORMULATION, CANISTER AND INHALER CONTAINING THE FORMULATION, AND METHOD OF USE | Kindeva Drug Delivery L.P. (US) | 2022-05-18 | — | — | EP | claimed |
| US-11304897-B2 | Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate | ANOVENT PHARMACEUTICAL (U.S.), LLC (US) | 2022-04-19 | — | — | US | claimed |
| WO-2022029403-A1 | PHARMACEUTICAL COMPOSITION | MEXICHEM UK LIMITED (GB) | 2022-02-10 | — | — | WO | claimed |
| WO-2022023291-A1 | METHOD FOR THE PURIFICATION OF VILANTEROL TRIFENATATE | INKE, S.A. (ES) | 2022-02-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434194-B2 | Amorphous form of vilanterol trifenatate and processes for the preparation thereof | VAT1, UBE2V1, VIL1 | ADRB2 743/4885ADRB1 389/4885ADRB3 568/4885 |
| US-11369760-B2 | Inhalation atomizer comprising a blocking function and a counter | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885ADRB3 6/4885 |
| US-11414374-B2 | Crystalline forms of vilanterol trifenatate and processes for their preparation | PRKCD, PRKCQ, CYP24A1 | ADRB2 131/4885ADRB1 334/4885ADRB3 119/4885 |
| US-11304897-B2 | Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate | PDCD2L, UROD, UFL1 | ADRB2 97/4885ADRB1 155/4885ADRB3 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.